tradingkey.logo
๎™

Ligand Pharmaceuticals Inc

LGND
191.130USD
-0.180-0.09%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
3.71B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

Ligand Pharmaceuticals Inc

191.130
-0.180-0.09%
TradingKey ์ฃผ์‹ ์ ์ˆ˜
๊ฑด๊ฐ•
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
์œ ์‚ฌ ์ข…๋ชฉ
TradingKey ์ฃผ์‹ ์ ์ˆ˜
๊ฑด๊ฐ•
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
์œ ์‚ฌ ์ข…๋ชฉ

TradingKey Ligand Pharmaceuticals Inc ์ฃผ์‹ ์ ์ˆ˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

ํšŒ์‚ฌ์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•„์ฃผ ๊ฑด์ „ํ•œํ•œ ํŽธ์ž…๋‹ˆ๋‹ค. ํšŒ์‚ฌ์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ์œผ๋กœ ๊ฐ„์ฃผ๋ฉ๋‹ˆ๋‹ค. ๊ธฐ๊ด€์˜ ์ธ์ง€๋„๋Š” ๋งค์šฐ ๋†’์€์ž…๋‹ˆ๋‹ค. ์ง€๋‚œ 30์ผ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์ด ์ด ํšŒ์‚ฌ๋ฅผ ๋งค์ˆ˜๋กœ ํ‰๊ฐ€ํ–ˆ์Šต๋‹ˆ๋‹ค. ํ‰๊ท ์ ์ธ ์ฃผ์‹์‹œ์žฅ ์„ฑ๊ณผ์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ , ํšŒ์‚ฌ๋Š” ๊ฐ•ํ•œ ํŽ€๋”๋ฉ˜ํ„ธ๊ณผ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๋ฅผ ๋ณด์ด๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Ligand Pharmaceuticals Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
2 / 159
์ „์ฒด ์ˆœ์œ„
16 / 4618
์‚ฐ์—…
์ œ์•ฝ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๋ฐ์ดํ„ฐ ์—†์Œ

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

7 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
183.125
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
-4.28%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

Ligand Pharmaceuticals Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
์†์‹ค ์ „ํ™˜
ํšŒ์‚ฌ์˜ ์‹ค์ ์ด ์ ์ž๋กœ ์ „ํ™˜๋˜์–ด, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์†์‹ค์€ ๋ฏธํ™” ๋‹ฌ๋Ÿฌ์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค
๊ณผ์†Œ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -46.81๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋‚ฎ์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 19.64M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 2.90% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
Private Capital๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž Private Capital์ด(๊ฐ€) ์ด ์ฃผ์‹ 229.25K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์‹œ์žฅ ํ™œ๋™ ์ฆ๊ฐ€
ํšŒ์‚ฌ๋Š” ํˆฌ์ž์ž๋“ค์˜ ๊ด€์‹ฌ์ด ๋†’์•„์ ธ, ์ตœ๊ทผ 20์ผ๊ฐ„ ํšŒ์ „์œจ์ด 1.11์ž…๋‹ˆ๋‹ค.

์žฌ๋ฌด ๊ฑด์ „์„ฑ๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

ํšŒ์‚ฌ์˜ ํ˜„์žฌ ์žฌ๋ฌด ์ ์ˆ˜๋Š” 9.11์ด๋ฉฐ, ์ด๋Š” ์ œ์•ฝ ์—…๊ณ„ ํ‰๊ท ์ธ 7.76๋ณด๋‹ค ์ด์ƒ์ž…๋‹ˆ๋‹ค. ํšŒ์‚ฌ์˜ ์žฌ๋ฌด ์ƒํƒœ๋Š” ๊ฒฌ๊ณ ํ•œ์ž…๋‹ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ํšŒ์‚ฌ์˜ ์šด์˜ ํšจ์œจ์„ฑ์€ ์ƒ๋‹จ์ž…๋‹ˆ๋‹ค. ํšŒ์‚ฌ์˜ ์ตœ์‹  ๋ถ„๊ธฐ ๋งค์ถœ์€ 47.63M๋ฅผ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ์ด๋Š” ์ „๋…„ ๋Œ€๋น„ 14.68%์˜ ์ฆ๊ฐ€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ํ•œํŽธ, ์ˆœ์ด์ต์€ ์ „๋…„ ๋Œ€๋น„ 109.34%์˜ ์ฆ๊ฐ€๋ฅผ ๋ณด์˜€์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
9.11
๋ณ€๊ฒฝ
0
๎™ธ

์žฌ๋ฌด ์ •๋ณด

๎˜ญ8.16

๊ด€๋ จ ์ง€ํ‘œ

ํ˜„๊ธˆ ๋ฐ ํ˜„๊ธˆ์„ฑ ์ž์‚ฐ
์ด ์ž์‚ฐ
๋ถ€์ฑ„ ์ด๊ณ„
์ž์œ  ํ˜„๊ธˆ ํ๋ฆ„
๋ฐ์ดํ„ฐ ์—†์Œ
๎™น

์ˆ˜์ต์˜ ์งˆ

๎˜ญ10.00
๎™น

์šด์˜ ํšจ์œจ์„ฑ

๎˜ญ10.00
๎™น

์„ฑ์žฅ ์ž ์žฌ๋ ฅ

๎˜ญ9.73
๎™น

์ฃผ์ฃผ ์ˆ˜์ต๋ฅ 

๎˜ญ7.65

Ligand Pharmaceuticals Inc ๊ธฐ์—… ๊ฐ€์น˜ ํ‰๊ฐ€๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

ํšŒ์‚ฌ์˜ ํ˜„์žฌ ๋ฐธ๋ฅ˜์—์ด์…˜ ์ ์ˆ˜๋Š” 7.25์ด๋ฉฐ, ์ด๋Š” ์ œ์•ฝ ์—…๊ณ„ ํ‰๊ท ์ธ 7.21๋ณด๋‹ค ์ด์ƒ์ž…๋‹ˆ๋‹ค. ํ˜„์žฌ ์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ(P/E)์€ -46.81๋กœ, ์ตœ๊ทผ ๊ณ ์  59.46 ๋Œ€๋น„ -227.04% ๋‚ฎ๊ณ , ์ตœ๊ทผ ์ €์  -554.46 ๋Œ€๋น„ -1084.59% ๋†’์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.25
๋ณ€๊ฒฝ
0

๋ฐธ๋ฅ˜์—์ด์…˜

์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
P/B
์ฃผ๊ฐ€๋งค์ถœ๋น„์œจ
์ฃผ๊ฐ€ํ˜„๊ธˆํ๋ฆ„๋น„์œจ
์‚ฐ์—… ์ˆœ์œ„ 2/159
๋ฐ์ดํ„ฐ ์—†์Œ

์˜ˆ์ƒ๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

ํšŒ์‚ฌ์˜ ํ˜„์žฌ ์‹ค์  ์ „๋ง ์ ์ˆ˜๋Š” 8.57์ด๋ฉฐ, ์ด๋Š” ์ œ์•ฝ ์—…๊ณ„ ํ‰๊ท ์ธ 7.78๋ณด๋‹ค ์ด์ƒ์ž…๋‹ˆ๋‹ค. Ligand Pharmaceuticals Inc์˜ ํ‰๊ท  ๋ชฉํ‘œ๊ฐ€๋Š” 180.00์ด๋ฉฐ, ์ตœ๊ณ ๊ฐ€๋Š” 206.00, ์ตœ์ €๊ฐ€๋Š” 164.00์ž…๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
8.57
๋ณ€๊ฒฝ
0

๋ชฉํ‘œ๊ฐ€

๋ฐ์ดํ„ฐ ์—†์Œ

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

7 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
183.125
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
-4.28%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

169
์ด๊ณ„
6
์ค‘๊ฐ„
8
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
Ligand Pharmaceuticals Inc
LGND
7
Biogen Inc
BIIB
36
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
32
AbbVie Inc
ABBV
31
1
2
3
...
34

์žฌ๋ฌด ์˜ˆ์ธก

EPS
์ˆ˜์ต
์ˆœ์ด์ต
EBIT
๋ฐ์ดํ„ฐ ์—†์Œ

๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

๋ชจ๋ฉ˜ํ…€๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

์ด ํšŒ์‚ฌ์˜ ํ˜„์žฌ ์ฃผ๊ฐ€ ๋ชจ๋ฉ˜ํ…€ ์ ์ˆ˜๋Š” 9.11์ด๋ฉฐ, ์ด๋Š” ์ œ์•ฝ ์—…์ข… ํ‰๊ท  7.02๋ณด๋‹ค ์ด์ƒ์ž…๋‹ˆ๋‹ค. ํšก๋ณด: ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 198.05 ์ €ํ•ญ์„ ๊ณผ 180.96 ์ง€์ง€์„  ์‚ฌ์ด์—์„œ ๊ฑฐ๋ž˜๋˜๊ณ  ์žˆ์–ด, ๊ตฌ๊ฐ„ ๋งค๋งค(Swing Trading)์— ์ ํ•ฉํ•œ ํ๋ฆ„์„ ๋ณด์ด๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.38
๋ณ€๊ฒฝ
1.73

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๋ฐ์ดํ„ฐ ์—†์Œ

์ง€ํ‘œ

๎˜ฐ
๎˜ฐ

์ง€ํ‘œ ๊ธฐ๋Šฅ์€ ๋‹ค์–‘ํ•œ ๊ธฐ๋ฒ• ์ง€ํ‘œ๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ ์—ฌ๋Ÿฌ ์ข…๋ชฉ์— ๋Œ€ํ•œ ๊ฐ€์น˜์™€ ๋ฐฉํ–ฅ ๋ถ„์„์„ ์ œ๊ณตํ•˜๋ฉฐ, ๊ธฐ์ˆ ์  ์š”์•ฝ๋„ ํ•จ๊ป˜ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.

์ด ๊ธฐ๋Šฅ์—๋Š” ์ผ๋ฐ˜์ ์œผ๋กœ ์‚ฌ์šฉ๋˜๋Š” 9๊ฐ€์ง€ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๊ฐ€ ํฌํ•จ๋ฉ๋‹ˆ๋‹ค: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX, MA. ๋˜ํ•œ ํ•„์š”์— ๋”ฐ๋ผ ์‹œ๊ฐ„ ํ”„๋ ˆ์ž„์„ ์กฐ์ •ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ธฐ์ˆ  ๋ถ„์„์€ ํˆฌ์ž ์ฐธ์กฐ์˜ ์ผ๋ถ€์ผ ๋ฟ์ด๋ฉฐ, ๋ฐฉํ–ฅ์„ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•ด ์ˆซ์ž ๊ฐ’์„ ์‚ฌ์šฉํ•˜๋Š” ๋ฐ์—๋Š” ์ ˆ๋Œ€์ ์ธ ๊ธฐ์ค€์ด ์—†์Šต๋‹ˆ๋‹ค. ๊ฒฐ๊ณผ๋Š” ์ฐธ์กฐ์šฉ์ผ ๋ฟ์ด๋ฉฐ, ์ง€ํ‘œ ๊ณ„์‚ฐ ๋ฐ ์š”์•ฝ์˜ ์ •ํ™•์„ฑ์— ๋Œ€ํ•ด์„œ๋Š” ์ฑ…์ž„์ง€์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

์ง€ํ‘œ
๋งค๋„(1)
์ค‘๋ฆฝ(3)
๋งค์ˆ˜(2)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-0.467
์ค‘๋ฆฝ
RSI(14)
66.818
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
66.750
์ค‘๋ฆฝ
ATR(14)
5.942
๊ณ ๋ณ€๋™์„ฑ
CCI(14)
123.083
๋งค์ˆ˜
Williams %R
18.765
๊ณผ๋งค๋„
TRIX(12,20)
0.348
๋งค๋„
StochRSI(14)
66.391
๋งค์ˆ˜
์ด๋™ ํ‰๊ท 
๋งค๋„(0)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(6)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
188.346
๋งค์ˆ˜
MA10
187.293
๋งค์ˆ˜
MA20
184.488
๋งค์ˆ˜
MA50
174.276
๋งค์ˆ˜
MA100
152.354
๋งค์ˆ˜
MA200
130.887
๋งค์ˆ˜

๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

ํšŒ์‚ฌ์˜ ํ˜„์žฌ ๊ธฐ๊ด€ ์ธ์ง€๋„ ์ ์ˆ˜๋Š” 10.00์ด๋ฉฐ, ์ด๋Š” ์ œ์•ฝ ์—…๊ณ„ ํ‰๊ท ์ธ 5.81๋ณด๋‹ค ์ด์ƒ ์ˆ˜์ค€์ž…๋‹ˆ๋‹ค. ์ตœ์‹  ๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ  ๋น„์œจ์€ 100.24%์ด๋ฉฐ, ์ด๋Š” ๋ถ„๊ธฐ ๋Œ€๋น„ ๊ฐ์†Œ 1.85%์ž…๋‹ˆ๋‹ค. ์ตœ๋Œ€ ๊ธฐ๊ด€ ์ฃผ์ฃผ๋Š” ๋” ๋ฑ…๊ฐ€๋“œ๋กœ, ์ด 2.08M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ ์ด๋Š” ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 10.64%์— ํ•ด๋‹นํ•ฉ๋‹ˆ๋‹ค. ๋ณด์œ  ์ง€๋ถ„์€ 3.43% ๊ฐ์†Œ๋ฅผ ๊ธฐ๋กํ–ˆ์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
10.00
๋ณ€๊ฒฝ
0

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์ฃผ ํ™œ๋™

์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
Chg %
BlackRock Institutional Trust Company, N.A.
2.65M
-0.72%
The Vanguard Group, Inc.
Star Investors๎˜ฏ
2.08M
+1.62%
Janus Henderson Investors
1.06M
+3.23%
Macquarie Investment Management
926.55K
+2.24%
State Street Investment Management (US)
749.75K
+3.11%
Dimensional Fund Advisors, L.P.
704.52K
-5.42%
Congress Asset Management Company, LLP
647.94K
+0.81%
Chicago Capital, LLC
571.83K
+3.12%
Stephens Investment Management Group, LLC
604.81K
-0.40%
MFS Investment Management
339.74K
+22.30%
1
2

์œ„ํ—˜ ์š”์†Œ๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-10-31

ํšŒ์‚ฌ์˜ ํ˜„์žฌ ๋ฆฌ์Šคํฌ ํ‰๊ฐ€ ์ ์ˆ˜๋Š” 7.60์ด๋ฉฐ, ์ด๋Š” ์ œ์•ฝ ์‚ฐ์—… ํ‰๊ท ์ธ 5.15๋ณด๋‹ค ์ด์ƒ ์ˆ˜์ค€์ž…๋‹ˆ๋‹ค. ํšŒ์‚ฌ์˜ ๋ฒ ํƒ€ ๊ฐ’์€ 0.96์ž…๋‹ˆ๋‹ค. ์ด๋Š” ํ•ด๋‹น ์ฃผ์‹์ด ์ƒ์Šน์žฅ์—์„œ๋Š” ์ง€์ˆ˜ ๋Œ€๋น„ ์ƒ๋Œ€์ ์œผ๋กœ ์ €์กฐํ•œ ์„ฑ๊ณผ๋ฅผ ๋‚ด์ง€๋งŒ, ํ•˜๋ฝ์žฅ์—์„œ๋Š” ๋” ์ž‘์€ ํญ์˜ ํ•˜๋ฝ์— ๊ทธ์น˜๋Š” ๊ฒฝํ–ฅ์ด ์žˆ์Œ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.60
๋ณ€๊ฒฝ
0
S&P 500 ์ง€์ˆ˜ ๋Œ€๋น„ ๋ฒ ํƒ€๊ฐ’
0.96
VaR
+4.43%
240์ผ ์ตœ๋Œ€ ๋‚™ํญ
+22.56%
240์ผ ๋ณ€๋™์„ฑ
+44.35%

๋Œ์•„๊ฐ€๊ธฐ

์ตœ๊ณ  ์ผ๊ฐ„ ์ˆ˜์ต๋ฅ 
60์ผ
+3.86%
120์ผ
+6.32%
5๋…„
+19.86%
์ตœ์ € ์ผ๊ฐ„ ์ˆ˜์ต๋ฅ 
60์ผ
-2.52%
120์ผ
-6.14%
5๋…„
-19.63%
์ƒคํ”„ ๋น„์œจ
60์ผ
+5.62
120์ผ
+4.34
5๋…„
+0.39

์œ„ํ—˜ ์š”์†Œ

์ตœ๋Œ€ ๋‚™ํญ
240์ผ
+22.56%
3๋…„
+37.51%
5๋…„
+65.47%
์ˆ˜์ต ๋Œ€๋น„ ๋‚™ํญ ๋น„์œจ
240์ผ
+2.91
3๋…„
+1.82
5๋…„
+0.35
์™œ๋„
240์ผ
-0.24
3๋…„
+0.59
5๋…„
+0.22

๋ณ€๋™์„ฑ

์‹คํ˜„ ๋ณ€๋™์„ฑ
240์ผ
+44.35%
5๋…„
+49.23%
ํ‘œ์ค€ํ™”๋œ ์ง„ํญ ๋ฒ”์œ„
240์ผ
+2.48%
5๋…„
+1.89%
ํ•˜๋ฐฉ ๋ฆฌ์Šคํฌ ์กฐ์ • ์ˆ˜์ต๋ฅ 
120์ผ
+759.76%
240์ผ
+759.76%
์ตœ๊ณ  ์ผ๊ฐ„ ์ƒ์Šน ๋ณ€๋™์„ฑ
60์ผ
+19.78%
์ตœ๊ณ  ์ผ๊ฐ„ ํ•˜๋ฝ ๋ณ€๋™์„ฑ
60์ผ
+23.17%

์œ ๋™์„ฑ

ํ‰๊ท  ํšŒ์ „์œจ
60์ผ
+1.09%
120์ผ
+0.87%
5๋…„
--
ํšŒ์ „์œจ ํŽธ์ฐจ
20์ผ
+110.83%
60์ผ
+48.04%
120์ผ
+16.96%

์œ ์‚ฌ ์ข…๋ชฉ
๎˜ฐ๎˜ฐ

์ œ์•ฝ
๎™
Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Inc
LGND
8.66 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
REGN
8.82 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc
RYTM
8.66 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.65 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Innoviva Inc
Innoviva Inc
INVA
8.59 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
8.58 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
๋” ๋ณด๊ธฐ
tradingkey.logo
๋‹น์ผ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” Refinitiv์—์„œ ์ œ๊ณตํ•˜๋ฉฐ, ์ด์šฉ ์•ฝ๊ด€์ด ์ ์šฉ๋ฉ๋‹ˆ๋‹ค. ์—ญ์‚ฌ์  ๋ฐ ํ˜„์žฌ ์ข…๊ฐ€ ๋ฐ์ดํ„ฐ๋Š” Refinitiv์—์„œ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ชจ๋“  ์‹œ์„ธ๋Š” ํ˜„์ง€ ๊ฑฐ๋ž˜์†Œ ์‹œ๊ฐ„ ๊ธฐ์ค€์ž…๋‹ˆ๋‹ค. ๋ฏธ๊ตญ ์ฃผ์‹ ์‹œ์„ธ์˜ ์‹ค์‹œ๊ฐ„ ๋งˆ์ง€๋ง‰ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” Nasdaq์„ ํ†ตํ•ด ๋ณด๊ณ ๋œ ๊ฑฐ๋ž˜๋งŒ ๋ฐ˜์˜๋ฉ๋‹ˆ๋‹ค. ๋‹น์ผ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” ์ตœ์†Œ 15๋ถ„ ์ง€์—ฐ๋˜๊ฑฐ๋‚˜ ๊ฑฐ๋ž˜์†Œ ์š”๊ตฌ ์‚ฌํ•ญ์— ๋”ฐ๋ผ ๋‹ค๋ฅผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
* ์ฐธ๊ณ ์ž๋ฃŒ, ๋ถ„์„ ๋ฐ ํŠธ๋ ˆ์ด๋”ฉ ์ „๋žต์€ ์ œ3์ž ์ œ๊ณต์—…์ฒด์ธ Trading Central์—์„œ ์ œ๊ณตํ•˜๋ฉฐ, ๋ถ„์„๊ฐ€์˜ ๋…๋ฆฝ์ ์ธ ํ‰๊ฐ€์™€ ํŒ๋‹จ์— ๊ธฐ๋ฐ˜ํ•œ ์‹œ๊ฐ์œผ๋กœ, ํˆฌ์ž์ž์˜ ํˆฌ์ž ๋ชฉํ‘œ์™€ ์žฌ์ • ์ƒํ™ฉ์€ ๊ณ ๋ ค๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ 
KeyAI
๎™